Results 251 to 260 of about 12,220,634 (288)

Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors

Chest, 2004
To compare the direct pulmonary vasodilating activity and specificity of phosphodiesterase-5 (zaprinast) and phosphodiesterase-3 (milrinone) inhibitors on the pulmonary vascular (PV) bed of the spontaneously breathing cat with an intact chest.Prospective, randomized animal study.Laboratory of university hospital.Experiments were performed in vivo in ...
Idit, Matot, Yaacov, Gozal
openaire   +2 more sources

Advances in the development of phosphodiesterase 5 inhibitors

European Journal of Medicinal Chemistry
Phosphodiesterase 5 (PDE5) can hydrolyze cyclic guanosine monophosphate (cGMP), which is critical for maintaining various physiological processes in organisms. Currently, clinically approved indications for PDE5 inhibitors encompass therapeutic agents for erectile dysfunction (ED), symptoms associated with lower urinary tract symptoms (LUTS), and ...
Tieqiang, Zong, Xing, Huang, Wei, Zhou, Zhengyu, Hu, Long, Jin, Peng, Zhan, Yuqing, Zhao, Jinfeng, Sun, Gao, Li   +8 more
openaire   +2 more sources

The use of phosphodiesterase 5 inhibitors with concomitant medications

Journal of Endocrinological Investigation, 2008
The phosphodiesterase-5 inhibitors (PDE5i) sildenafil, vardenafil, and tadalafil are considered first-line therapy for the treatment of patients with erectile dysfunction (ED). In addition to the classical pro-erectile-effect, clinical findings have suggested that they can also influence vascular tone in pulmonary, coronary and other vascular tissues ...
G. Corona, E. Razzoli, FORTI, GIANNI, MAGGI, MARIO   +3 more
openaire   +3 more sources

Phosphodiesterase Type 5 Inhibitors: The Day After

European Urology, 2007
Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis, Dimitrios, Hatzichristou   +1 more
openaire   +2 more sources

Key Features for Designing Phosphodiesterase-5 Inhibitors

Journal of Biomolecular Structure and Dynamics, 2010
Phosphodiesterase superfamily is the key regulator of 3',5'-cyclic guanosine monophosphate (cGMP) decomposition in human body. Phosphodiesterase-5 (PDE-5) inhibitors, sildenafil, vardenafil and tadalafil, are well known oral treatment for males with erectile dysfunction.
Tung-Ti, Chang, Hung-Jin, Huang, Kuei-Jen, Lee, Hsin Wei, Yu, Hsin-Yi, Chen, Fuu-Jen, Tsai, Mao-Feng, Sun, Calvin Yu-Chian, Chen   +7 more
openaire   +2 more sources

Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors

Expert Opinion on Pharmacotherapy, 2011
At the present time, inhibitors of phosphodiesterase type 5 (PDE5) have Food and Drug Administration approval only for the treatment of erectile dysfunction and pulmonary artery hypertension, for which their mechanism of action is vasodilation and augmentation of blood flow by impeding PDE5-mediated breakdown of cyclic guanosine monophosphate. However,
Robert A, Kloner, Gary, Comstock, Laurence A, Levine, Steven, Tiger, Vera J, Stecher   +4 more
openaire   +2 more sources

In Defense of Phosphodiesterase 5 Inhibitors—Reply

JAMA Ophthalmology, 2022
Mohit, Sodhi, Frederick S, Mikelberg, Mahyar, Etminan   +2 more
openaire   +2 more sources

Sildenafil and phosphodiesterase-5 inhibitors for heart failure

Current Heart Failure Reports, 2008
Treatment of heart failure (HF) is a challenging task. An impaired nitric oxide pathway contributes to several abnormal cardiac and vascular phenotypes typical of the failing cardiovascular system. Inhibition of phosphodiesterase-5 (PDE5) is a new therapeutic strategy for overexpressing nitric oxide signaling by increasing the availability of cyclic ...
openaire   +2 more sources

Prescribing of Phosphodiesterase-5 Inhibitors Among Psychiatrists

Journal of Sex & Marital Therapy, 2013
Phosphodiesterase-5 (PDE-5) inhibitors—avanafil, sildenafil, tadalafil, and vardenafil—are approved and widely used for treatment of erectile dysfunction of various etiologies.
Richard, Balon, Mary K, Morreale, R Taylor, Segraves   +2 more
openaire   +2 more sources

Phosphodiesterase‐5 Inhibitors and Migraine

Headache: The Journal of Head and Face Pain, 2004
Evans, Randolph W, Kruuse, Christina Rostrup   +1 more
openaire   +3 more sources